Belite Bio Inc ADR

37.69+6.55+21.03%Vol 100.84K1Y Perf -
Jul 1st, 2022 16:00 DELAYED
BID32.20 ASK37.49
Open32.00 Previous Close31.14
Pre-Market- After-Market36.99
 - -  -0.70 -1.86%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
109.43 
Earnings Rating
Market Cap908.14M 
Earnings Date
-
Alpha Standard Deviation
Beta 

Today's Price Range

31.0037.80

52W Range

8.8035.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
9.95%
1 Month
153.80%
3 Months
-
6 Months
-
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BLTE37.696.550021.03
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume100.84K
Shares Outstanding24.10K
Shares Float24.10M
Trades Count1.99K
Dollar Volume3.42M
Avg. Volume221.38K
Avg. Weekly Volume127.41K
Avg. Monthly Volume98.22K
Avg. Quarterly Volume438.50K

Belite Bio Inc ADR (NASDAQ: BLTE) stock closed at 37.69 per share at the end of the most recent trading day (a 21.03% change compared to the prior day closing price) with a volume of 100.84K shares and market capitalization of 908.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Belite Bio Inc ADR CEO is .

The one-year performance of Belite Bio Inc ADR stock is %, while year-to-date (YTD) performance is %. BLTE stock has a five-year performance of %. Its 52-week range is between 8.8 and 35.2, which gives BLTE stock a 52-week price range ratio of 109.43%

Belite Bio Inc ADR currently has a PE ratio of -74.60, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -43.85%, a ROC of -% and a ROE of 87.36%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Belite Bio Inc ADR, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Belite Bio Inc ADR’s next earnings report date is -.

The consensus rating of Wall Street analysts for Belite Bio Inc ADR is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Belite Bio Inc ADR stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Belite Bio Inc ADR has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Belite Bio Inc ADR has a Neutral technical analysis rating based on Technical Indicators (ADX : 62.22, ATR14 : 3.30, CCI20 : 113.14, Chaikin Money Flow : 0.47, MACD : 4.82, Money Flow Index : 73.83, ROC : 33.65, RSI : 75.47, STOCH (14,3) : 99.42, STOCH RSI : 0.49, UO : 69.64, Williams %R : -0.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Belite Bio Inc ADR in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Belite Bio Inc ADR

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

CEO:

Telephone: +1 858 246-6240

Address: 5820 Oberlin Drive, San Diego 92121, CA, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

50%50%

Bearish Bullish

33%67%

News

Stocktwits